Stock BMYB34 BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bristol-Myers Squibb Company Sao Paulo

Equities

BMYB34

BRBMYBBDR000

Market Closed - Sao Paulo
Other stock markets
 09:18:13 28/06/2024 pm IST 		5-day change 1st Jan Change
233 BRL +1.74% Intraday chart for Bristol-Myers Squibb Company +2.42% -6.77%
27/06 Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise MT
26/06 2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • The company has a low valuation given the cash flows generated by its activity.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • The company appears highly valued given the size of its balance sheet.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-6.77% 84.19B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 641B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.04% 224B
A+
NOVARTIS AG Stock Novartis AG
+13.31% 218B
B-
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BMYB34 Stock
  5. Ratings Bristol-Myers Squibb Company